Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

The FSH component binds to receptors on ovarian granulosa cells, promoting follicle growth and estrogen production. The LH component activates receptors on theca cells and triggers the luteinizing surge that leads to final follicle maturation and ovulation. Together they coordinate the hormonal cascade required for successful conception.

The dose of Meriofert is individualized by the prescribing clinician based on the patient’s ovarian response, treatment protocol, and underlying condition. Healthcare providers determine the amount, frequency, and duration of therapy after evaluating clinical parameters and monitoring results.

Meriofert is intended for use before pregnancy to facilitate conception. Its safety in established pregnancy has not been established, and it is generally not recommended during pregnancy. Limited data exist for breastfeeding; therefore, use while nursing should be discussed with a qualified healthcare professional.

To place an order, submit an enquiry on the Meriofert product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and required import documentation.

Meriofert combines both FSH and LH activity in a single preparation, whereas some alternatives provide only FSH (e.g., recombinant FSH) or separate LH supplementation. The combined formulation can simplify dosing schedules and may better mimic natural ovarian physiology, but the choice depends on individual patient response and clinician preference.

Meriofert should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze the product or shake the vial vigorously. Keep it in the original packaging until use to maintain stability and potency.

Meriofert is supplied as a sterile injectable solution and is administered either intramuscularly or subcutaneously, as directed by the prescribing clinician. The injection site and technique are chosen based on patient comfort and the specific treatment protocol.

The most serious risks include severe ovarian hyperstimulation syndrome, which can cause rapid ovarian enlargement, fluid shifts, and thromboembolic complications, as well as rare allergic reactions such as anaphylaxis. Prompt medical attention is required if symptoms of these conditions develop.

Meriofert is contraindicated in individuals with known hypersensitivity to its components, active malignancy, uncontrolled thyroid disease, or severe cardiovascular disorders. It should also be avoided in patients with ovarian cysts that could rupture or in those where pregnancy is already confirmed.